A Single Center, Three Period, Randomized, Three-way Crossover, Double-blind Placebo And Moxifloxacincontrolled Study To Assess The Effects Of Effexor XR On Cardiac Repolarization In Healthy Adult Subjects

Trial Profile

A Single Center, Three Period, Randomized, Three-way Crossover, Double-blind Placebo And Moxifloxacincontrolled Study To Assess The Effects Of Effexor XR On Cardiac Repolarization In Healthy Adult Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Aug 2016

At a glance

  • Drugs Venlafaxine (Primary) ; Moxifloxacin
  • Indications Generalised anxiety disorder; Major depressive disorder; Panic disorder; Social phobia
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 17 Aug 2016 Status changed from active, no longer recruiting to completed.
    • 08 Jun 2016 Status changed from recruiting to active, no longer recruiting.
    • 16 May 2016 Planned End Date changed from 1 Aug 2016 to 1 Jul 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top